GSK Sees Big Opportunity In OTC Diet Aids: Xenical Switch NDA Filed
This article was originally published in The Pink Sheet Daily
Firm filed an NDA for orlistat 60 mg OTC switch in June, CEO Garnier says during July 28 earnings call. A successful switch bid could depend on GSK’s ability to address self-treatment concerns.
You may also be interested in...
The firm will restate first quarter and 2004 year-end results due to less-than-expected returns of the anabolic agent.
FDA approves bisphosphonate line extension featuring four days of risedronate dosing and 24 days of calcium supplementation.
A committee comprising stakeholders will discuss ways of improving USP's work with international pharmacopeias to harmonize excipient monographs and general chapters.